News & Updates

Show Multimedia Only

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

05 Nov 2025 by

Treatment with tislelizumab results in longer overall survival (OS), prolonged progression-free survival (PFS), higher objective response rates (ORRs), more durable responses, and fewer grade ≥3 treatment-emergent (TEAEs) and treatment-related adverse events (TRAEs) compared with docetaxel, according to the RATIONALE-303 study.

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

05 Nov 2025

World’s first RCT on lipofilling in breast-conserving surgery shows promising preliminary results

05 Nov 2025 by

The world’s first randomized controlled trial (RCT) of lipofilling for immediate breast reconstruction in breast-conserving surgery (BCS), conducted by researchers from the University of Hong Kong (HKU), has shown promising preliminary results and continues to recruit patients.

World’s first RCT on lipofilling in breast-conserving surgery shows promising preliminary results

05 Nov 2025

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

04 Nov 2025 by

Neoadjuvant treatment with tiragolumab plus atezolizumab, with or without chemotherapy, is feasible in advanced resectable non-small cell lung cancer (NSCLC), having an acceptable safety profile and yielding major pathologic response (MPR) rates comparable to that observed with other perioperative immunotherapy plus chemotherapy regimens, according to the phase II SKYSCRAPER-05 trial.

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

04 Nov 2025

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

04 Nov 2025

Some patients with nonsmall-cell lung cancer (NSCLC) have somatic DNA methyltransferase 3A (DNMT3A) mutations, which are associated with a reduced DNMT3A expression and a favourable immunophenotype, reveals a study.

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

04 Nov 2025

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

03 Nov 2025 by

In the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), the combination of cemiplimab plus chemotherapy continued to provide superior benefits compared with chemotherapy alone, according to 5-year data from the phase III EMPOWER-Lung part 2 trial.

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

03 Nov 2025

Extended PLND tied to improved survival in bladder cancer

03 Nov 2025

In patients with bladder cancer, extended pelvic lymph node dissection (PLND) is associated with favourable recurrence-free survival and 5-year recurrence rates, a study has shown.

Extended PLND tied to improved survival in bladder cancer

03 Nov 2025

AIH linked to higher lymphoma, myeloma risks, but not to extrahepatic malignancy

01 Nov 2025

Patients with autoimmune hepatitis (AIH) do not show an increased risk of overall extrahepatic malignancy compared with controls, but they appear to be at greater risk of lymphoma or myeloma, independent of immunosuppressant use, suggests a study.

AIH linked to higher lymphoma, myeloma risks, but not to extrahepatic malignancy

01 Nov 2025

Original New Drug Application Approvals by US FDA (16-30 September 2025)

31 Oct 2025

New drug applications approved by US FDA as of 16-30 September 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 September 2025)

31 Oct 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-September-2025

31 Oct 2025

New drug applications approved by US FDA as of 1-15 September 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-September-2025

31 Oct 2025

Mupirocin-based bacterial decolonization therapy takes on radiation-induced mouth sores

29 Oct 2025 by

Bacterial decolonization with mupirocin nasal ointment benefits nasopharyngeal carcinoma patients undergoing radiotherapy, reducing the incidence of acute radiation-induced oral mucositis (AROM) and improving quality of life by relieving pain and swallowing difficulties, according to an open-label phase III study.

Mupirocin-based bacterial decolonization therapy takes on radiation-induced mouth sores

29 Oct 2025

News & Updates

Filter by Specialty:

Specialty:

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

World’s first RCT on lipofilling in breast-conserving surgery shows promising preliminary results

World’s first RCT on lipofilling in breast-conserving surgery shows promising preliminary results

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

Extended PLND tied to improved survival in bladder cancer

Extended PLND tied to improved survival in bladder cancer

AIH linked to higher lymphoma, myeloma risks, but not to extrahepatic malignancy

AIH linked to higher lymphoma, myeloma risks, but not to extrahepatic malignancy

Original New Drug Application Approvals by US FDA (16-30 September 2025)

Original New Drug Application Approvals by US FDA (16-30 September 2025)

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-September-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-September-2025

Mupirocin-based bacterial decolonization therapy takes on radiation-induced mouth sores

Mupirocin-based bacterial decolonization therapy takes on radiation-induced mouth sores